Abbreviations
Oslo University Hospital is affiliated with the Faculty of Medicine of the University of Oslo and is one of the largest medical research institutions in Europe. Every year more than 700 patients are treated for brain tumours at the institution ranging across all treatment modalities. The hospital offers surgery with intraoperative MRI combined with advanced cognitive neuromonitoring, molecular diagnostics, advanced neuro-oncology in combinations with an early phase trial unit. Treatment is given as close to the patient as possible through a close collaboration with the regional hospitals and primary health care service.
What is OUS’ main role?
Exploring the use of a mRNA based dendritic cell immunotherapy targeting autologous cancer stem cells and the targets surviving and hTERT in combination with check point inhibition in patients with recurrent glioblastoma in a early phase trial
Identifying biological markers of immune response in previously treated long-term surviving patients from the dendritic cell-cellular adoptive immunotherapy for solid tumors (GBM) and dendritic stem cell trials
Which work packages is OUS involved in?
See our dedicated page for more details on the GLIOMATCH work plan.
OUS contributes primarily to work package 5 and supports work packages 2, 7 and 8
Who will represent OUS?
GLIOMATCH Partners
